- 2024.04.11
Press Releases
2024.04.05
ROCKVILLE, MD, April 5, 2024 – I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024. 23rd Annual Needham Virtual Healthcare Conference […]
2024.04.03
ROCKVILLE, MD, April 2, 2024 – I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all conditions precedent to the divestiture transaction previously announced on February 7, 2024 (the “Transaction”) have been either satisfied […]
2024.03.14
The Company announced financial results for the full year ended December 31, 2023, and highlighted recent business updates.
Events
I-Mab was established in June 2016
I-Mab completed Series A financing, raising $58 million
Third Venture Biopharma and Tasgen merged to form I-Mab, raising $120 million in Series B Financing
I-Mab successfully raised $227 million in Series C Financing
I-Mab was listed on the Nasdaq Global Market as a clinical-stage biotech company
I-Mab and AbbVie enter into global strategic partnership on development and commercialization of I-Mab's novel CD47 monoclonal antibody lemzoparlimab
I-Mab entered into $523 million private placement agreement with Hillhouse Capital-led consortium
I-Mab established its global footprint with 9 locations, including new R&D site in San Diego, and new GMP facility in Hangzhou
I-Mab and Jumpcan entered into a strategic partnership for commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China
I-Mab signed agreement to divest its assets and business operations in China, bringing a greater focus on the U.S. and ex-China markets